Asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukemia (ALL). Its influence on the coagulation system has been extensively studied. 1 Asparaginase is an enzyme leading to serum depletion of asparagine and glutamine. Consequently, protein synthesis is depressed leading to coagulation protein deficiencies as a side effect of antileukemic treatment. The effect on antithrombotic proteins might induce an increased risk for thrombosis, while the effects on procoagulant proteins might increase the bleeding risk. Asparaginase is usually given in combination with other chemotherapeutic drugs among which especially corticosteroids may also influence the coagulation system. Corticosteroids may induce hypofibrinogenemia potentially leading to bleeding, but also increase the risk for thrombotic events by the induction of a hypofibrinolytic state in combination with an increase in procoagulant factors. 2 So, in general, it is difficult to analyze which coagulation disorders in children with ALL are due to asparaginase and which are due to concomitant use of other drugs such as corticosteroids. In this study, we analyzed the influence of both these drugs (Paronal and dexamethasone) in one group of children during two different parts of ALL therapy.
During induction, according to the DCOG (Dutch Childhood Oncology Group)-ALL-9 treatment schedule, 3 24 children with high-risk ALL were treated with among others dexamethasone from day 1 to day 29 followed by 15 days of tapering to zero and four doses of Paronal (6000 IU/m 2 ) on days 29, 33, 36 and 40. During the intensification phase of this protocol, the treatment included one weekly dose of Paronal (10 000 IU/m 2 ) during 9 weeks and 7 days of dexamethasone once every 3 weeks during the same 9 weeks (Figure 1 ).
Blood samples were collected immediately before each Paronal infusion to analyze procoagulant (fibrinogen, F II, F V, F VII, F IX, F X) and anticoagulant factors (antithrombin, protein C, protein S) and parameters of thrombin generation (F1 þ 2, thrombin-antithrombin (TAT) complex) and fibrinolysis (a2-antiplasmin, plasminogen, plasmin-a2 antiplasmin (PAP) complex, D-dimer).
After 4 weeks of dexamethasone on day 29, all procoagulant and anticoagulant factors demonstrated high levels, and a hypofibrinogenemia was observed (Figures 2 and 3) . The four doses of Paronal and tapering of the dose of dexamethasone (days 29-43) had the following effects on the procoagulant parameters:
after an initial further decrease, fibrinogen levels stabilized at low levels or increased slightly ( Figure 2a) ; F V levels stabilized at high levels ( Figure 2b) ; F II, IX and X normalized ( Figure 2c) ; Figure 2 Plasma levels of procoagulant parameters during induction and intensification treatment. Plasma levels of fibrinogen (a), factor V (b) and vitamin K-dependent clotting factors (II, VII, IX and X; c) during the induction and the intensification phase of the DCOG-ALL-9 treatment schedule. During induction, dexamethasone 6 mg/m 2 was given for 4 weeks followed by tapering to zero in 15 days; Paronal 6000 IU/m 2 was given twice a week on days 29, 33, 36 and 40. Intensification started at day 104 with Paronal 10 000 IU/m 2 weekly and with 1 week dexamethasone 6 mg/m 2 every 3 weeks. The dexamethasone periods are drawn in gray, and arrows mark the Paronal infusions. Data are given as means with standard error of the means. Normal reference ranges are marked with dotted lines. Differences between groups were calculated using one-way analysis of variance with Bonferroni's multiple comparison test to determine significance; P ¼ 0.05 (two sided) was considered the limit of significance. The sign n refers to significant differences for comparison with previous measurements. only F VII increased to supranormal levels ( Figure 2c) ; the anticoagulant parameters (AT, protein C and S) and the fibrinolytic potential (plasminogen and a2-antiplasmin) decreased significantly leading to a hypercoagulable state (Figures 3a and b) ; as a result of decreased protein synthesis of plasminogen and a2-antiplasmin, PAP too decreased significantly ( Figure 3c) ; D-dimers demonstrated no changes, nor did TAT and F1 þ 2, pointing to no signs of increased fibrinolysis or thrombin generation (Figure 3c ).
In the intensification phase, only 11 children could be analyzed up to the sixth Paronal infusion because at that point already 13 of 24 children had switched to another asparaginase product (Erwinase or PEG-asparaginase) because of allergic reactions. Interestingly, the effect of 1 weekly dose of asparaginase with 1 week dexamethasone every 3 weeks during intensification was completely different compared to the effect during induction therapy, when dexamethasone was administered daily and asparaginase twice a week:
The levels of fibrinogen decreased significantly in relation to the 7-day administration of dexamethasone (Po0.0001) (Figure 2a ) and recovered during weekly asparaginase administration in the absence of dexamethasone. F V did not demonstrate any durable changes (Figure 2b ). F II, VII, IX and X increased during 1-week dexamethasone treatment and normalized afterwards during weekly administration of asparaginase (Figure 2c ).
Figure 3
Plasma levels of anticoagulant parameters, parameters of fibrinolysis and of thrombin generation during induction and intensification. Plasma levels of anticoagulant proteins (antithrombin, protein C, free protein S and total protein S; a) and of plasminogen and a2-antiplasmin (b). Data are given as means with standard error of the means. Normal reference ranges are marked with dotted lines. For the activation markers thrombin-antithrombin complex, F1 þ 2, plasmin-antiplasmin complex and D-dimers, data are given as medians with 25th and 75th percentiles (c). Normal reference ranges are shown in parenthesis. The dexamethasone periods are drawn in gray, and arrows mark the Paronal infusions. Differences between groups were calculated using one-way analysis of variance, with Bonferroni's multiple comparison test to determine significance; P ¼ 0.05 (two sided) was considered the limit of significance. The sign n refers to significant differences for comparison with previous measurements.
Letters to the Editor
The levels of anticoagulant proteins and plasminogen and a2-antiplasmin hardly changed during this treatment phase (Figures 3a and b) . No signs of increased thrombin generation and of fibrinolysis were monitored (Figure 3c ).
The half-life of Paronal has been calculated to be 23.072.5 h. 4 It could be speculated that once a week 10 000 IU/m 2 of Paronal would allow a recovery from diminished protein synthesis by asparaginase, while twice weekly 6000 IU/m 2 of Paronal would lead to a cumulative effect with no time for recovery. But, it could also be hypothesized that the higher dose of Paronal in the intensification phase would have led to prolonged inhibition of coagulation protein synthesis. Our data however showed that the schedule of Paronal once a week 10 000 IU/m 2 resulted only in minor changes in coagulation proteins. One week of dexamethasone every 3 weeks in the intensification phase only led to a significant decline in the level of fibrinogen (Figure 2a) , which was followed a week later by a significant increase, whereas the combination of Paronal and dexamethasone, as applied in induction, resulted in a severe decline in anticoagulant proteins and in a decreased fibrinolytic potential.
Based on these data, a hypercoagulable state was diagnosed during induction treatment only, whereas during intensification with a higher dose of Paronal in a weekly schedule combined with only 1 week of dexamethasone every 3 weeks, the risk for thrombosis was minimal. We conclude that there is a crucial interaction between asparaginase and dexamethasone in maintaining the balance between bleeding and thrombosis during therapy in childhood ALL and the effects on the coagulation system depend on the specific schedule of administration of these drugs.
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